Reported resultsCompany-reported
What was reported
Mountain View, Calif. – May 12, 2026 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
What the evidence supports
NeuroPace published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $22.1 million | “•Total revenue of $22.1 million in the quarter.” Mentions: revenue |
| $22.0 million | “Excluding DIXI Medical, total revenue of $22.0 million representing 20.1% year over year growth” Mentions: revenue |
| $21.7 million | “•RNS System revenue of $21.7 million in the quarter, representing 19.5% year over year growth” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue GuidanceU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
Press release lead paragraphMountain View, Calif. – May 12, 2026 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
Amount stated in press release•Total revenue of $22.1 million in the quarter.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
Amount stated in press releaseExcluding DIXI Medical, total revenue of $22.0 million representing 20.1% year over year growthU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
Amount stated in press release•RNS System revenue of $21.7 million in the quarter, representing 19.5% year over year growthU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 12, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.